In a phase I trial, EGFR-targeting CAR T cells were investigated in 16 patients with metastatic pancreatic cancer whose cells were EGFR-positive by immunohistochemistry (>50%) [104]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.